{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:57:18Z","timestamp":1781049438453,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003748","name":"Swedish Society for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016669","name":"Sj\u00f6berg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejso.2026.111424","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:03:14Z","timestamp":1769155394000},"page":"111424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis"],"prefix":"10.1016","volume":"52","author":[{"given":"Anna","family":"Constantinescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2689-4432","authenticated-orcid":false,"given":"Anne","family":"Huibers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejso.2026.111424_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.ejso.2026.111424_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","article-title":"Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy","volume":"12","author":"Pawlik","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2026.111424_bib3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American joint committee on cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"10.1016\/j.ejso.2026.111424_bib4","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s11912-024-01611-9","article-title":"Talimogene laherparepvec (T-VEC) and emerging intralesional immunotherapies for metastatic melanoma: a review","volume":"26","author":"Kalsi","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.ejso.2026.111424_bib5","article-title":"Clinical effectiveness and safety of electrochemotherapy (ECT) in the treatment of locally advanced melanoma: a systematic review","volume":"17","author":"Vickars","year":"2025","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ejso.2026.111424_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<238::AID-SSU8>3.0.CO;2-9","article-title":"Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion","volume":"14","author":"Thompson","year":"1998","journal-title":"Semin Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.111424_bib7","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","article-title":"Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit","volume":"148","author":"Creech","year":"1958","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.ejso.2026.111424_bib8","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","article-title":"Diagnosis and treatment of in-transit melanoma metastases","volume":"43","author":"Testori","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.111424_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10585-023-10234-6","article-title":"Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver","volume":"41","author":"Huibers","year":"2024","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"10.1016\/j.ejso.2026.111424_bib10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.2009-0325","article-title":"Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety","volume":"15","author":"Moreno-Ramirez","year":"2010","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejso.2026.111424_bib11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1245\/s10434-011-2030-7","article-title":"20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters","volume":"19","author":"Deroose","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.111424_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108050","article-title":"Technical considerations for isolated limb perfusion: a consensus paper","volume":"50","author":"Hayes","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"5256","key":"10.1016\/j.ejso.2026.111424_bib13","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"1a","key":"10.1016\/j.ejso.2026.111424_bib14","first-page":"61","article-title":"Immunotherapy of melanoma","volume":"22","author":"Lugowska","year":"2018","journal-title":"Contemp Oncol"},{"issue":"20","key":"10.1016\/j.ejso.2026.111424_bib15","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2026.111424_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14050442","article-title":"Isolated limb perfusion and immunotherapy in the treatment of In-Transit melanoma metastases: is it a real synergy?","volume":"14","author":"Rastrelli","year":"2024","journal-title":"J Personalized Med"},{"issue":"6","key":"10.1016\/j.ejso.2026.111424_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/02656736.2013.802374","article-title":"Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma","volume":"29","author":"Olofsson","year":"2013","journal-title":"Int J Hyperther"},{"issue":"6","key":"10.1016\/j.ejso.2026.111424_bib18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/01.sla.0000146147.89667.ed","article-title":"One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases","volume":"240","author":"Gr\u00fcnhagen","year":"2004","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.ejso.2026.111424_bib19","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1245\/s10434-010-1104-2","article-title":"Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases","volume":"17","author":"Rossi","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"24","key":"10.1016\/j.ejso.2026.111424_bib20","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1158\/0008-5472.CAN-15-1184","article-title":"Melphalan, antimelanoma immunity, and Inflammation--Letter","volume":"75","author":"Martner","year":"2015","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejso.2026.111424_bib21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3109\/02656736.2013.782428","article-title":"Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma","volume":"29","author":"Olofsson","year":"2013","journal-title":"Int J Hyperther"},{"issue":"6","key":"10.1016\/j.ejso.2026.111424_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108265","article-title":"The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: an interim analysis of a phase Ib\/II randomized double-blind placebo-controlled trial (NivoILP trial)","volume":"50","author":"Holmberg","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.111424_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2026.111424_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.molmed.2008.02.002","article-title":"Immunogenicity of anthracyclines: moving towards more personalized medicine","volume":"14","author":"Apetoh","year":"2008","journal-title":"Trends Mol Med"},{"issue":"3","key":"10.1016\/j.ejso.2026.111424_bib25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ejso.2026.111424_bib26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejso.2026.111424_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4049\/jimmunol.1701044","article-title":"Inhibitors of the PD-1 pathway in tumor therapy","volume":"200","author":"LaFleur","year":"2018","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.ejso.2026.111424_bib28","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1016\/j.ejso.2021.04.038","article-title":"Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma","volume":"47","author":"Kiffin","year":"2021","journal-title":"Eur J Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:18:02Z","timestamp":1776154682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0748798326000430"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111424","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111424"}}